Perioperative management of antiplatelet agents

Orthopedics

Volumn 35, Issue 8, 2012, Pages 687-691

  Mohr, Tyler S ^a   Brouse, Sara D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CLINICAL PRACTICE; CORONARY STENT; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ELECTIVE SURGERY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INFORMATION DISSEMINATION; LONG TERM CARE; MORBIDITY; MORTALITY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; SURGICAL APPROACH; SURGICAL TECHNIQUE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; CORONARY THROMBOSIS; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; STENTS; SURGICAL PROCEDURES, ELECTIVE; WITHHOLDING TREATMENT;

EID: 84865291660     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20120725-06     Document Type: Review

References (24)

1. Savonitto S, Caracciolo M, Cattaneo M, DE Servi S. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost. 2011; 9(11):2133-2142.
2. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol. 2007; 50(2):119-127.
3. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124(23):e574-e651.
4. United States Food and Drug Administration. Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Coronary Stent (1st archival). http://www.fda.gov/ MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm064528.htm. Published October 29, 2003. Accessed March 6, 2012.
5. United States Food and Drug Administration. Final Update of Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Sirolimus-eluting Coronary Stent. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ PublicHealthNotifications/ucm062120.htm. Published October 18, 2004. Accessed March 6, 2012.
6. Di Minno MN, Prisco D, Ruocco AL, Mastronardi P, Massa S, Di Minno G. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med. 2009; 4(4):279-288.
7. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 suppl):e326S-e350S.
8. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009. 53(16):1399-1409.
9. Bertrand ME. When and how to discontinue antiplatelet therapy. European Heart J Supplements. 2008. 10(A):A35-A41.
10. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006. 48(12):2584-2591.
11. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011; 112(2):292-318.
12. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004; 75(1):40-47.
13. Serebruany VL, Malinin AI, Ferguson JJ, Vahabi J, Atar D, Hennekens CH. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol. 2008; 22(3):315-321.
14. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502.
15. Plavix [package insert]. Bristol-Myers Squibb/Sanofi Pharmacieticals Partnership, Bridgewater, NJ; December 2011.
16. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 58(24):e123-e210.
17. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20):2001-2015.
18. Effient [package insert]. Eli Lilly and Company, Indianapolis, IN; September 2011. http://pi.lilly.com/us/effient.pdf.
19. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25):2577-2585.
20. Brillinta [package insert]. AstraZeneca, Wilmington, DE; July 2011. http://www1.astra-zeneca-us.com/pi/brilinta.pdf.
21. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011; 57(6):672-684.
22. Angiolillo DJ, Firstenberg MS, Price MJ, Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012; 307(3):265-274.
23. Rassi AN, Blackstone E, Militello MA, et al. Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery [published online ahead of print May 14, 2012]. Am J Cardiol. In press.
24. Pickett AM, Taylor DA, Ackman ML. Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature. Pharmacotherapy. 2010; 30(4):127e-133e.